Milestone Pharmaceuticals Inc. (MIST)
NASDAQ: MIST · Real-Time Price · USD
0.7572
-0.0070 (-0.92%)
At close: Oct 7, 2026, 4:00 PM EDT
0.763101
+0.0059 (0.78%)
After-hours: Oct 7, 2026, 7:59 PM EDT
Milestone Pharmaceuticals Revenue
Milestone Pharmaceuticals had revenue of $559.00K in the quarter ending June 30, 2026. This brings the company's revenue in the last twelve months to $2.34M. In the year 2025, Milestone Pharmaceuticals had annual revenue of $1.55M. That makes Milestone Pharmaceuticals the world's 42,025th largest company by revenue and 5,701st in the United States.
Revenue (ttm)
$2.34M
Revenue Growth
n/a
P/S Ratio
45.54
Revenue / Employee
$61,658
Employees
38
Market Cap
106.70M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.55M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 1.00M | -4.00M | -80.00% |
| Dec 31, 2022 | 5.00M | -10.00M | -66.67% |
| Dec 31, 2021 | 15.00M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
MIST News
- 13 days ago - Milestone announces Montreal Heart Institute enrolled first patient - TheFly
- 13 days ago - Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR - GlobeNewsWire
- 22 days ago - Milestone Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - Milestone Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference - Transcripts
- 4 weeks ago - Milestone Pharmaceuticals announces NMPA approval of etripamil for PSVT - TheFly
- 4 weeks ago - Milestone Pharmaceuticals Announces NMPA Approval of Etripamil Nasal Spray for PSVT in China, Marking First Regulatory Approval of Etripamil Outside of the United States - GlobeNewsWire
- 5 weeks ago - Milestone Pharmaceuticals to Present at Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal Supraventricular Tachycardia (PSVT) on Patients' Daily Lives and Quality of Life Between Episodes - GlobeNewsWire